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INTRODUCTION 
The NMDA receptor hypofunction hypothesis of schizophrenia was established 
after the observation that NMDA receptor antagonists such as phencyclidine 
(PCP) and ketamine can induce, in healthy individuals, altered behavioral states 
that resemble the positive and negative symptoms as well as the cognitive 
deficits seen in schizophrenia [1-3]. In addition, ketamine can heighten 
psychotic episodes in patients with schizophrenia [4-6]. In rodents, PCP and the 
more potent and selective noncompetitive NMDA receptor antagonist, 
dizocilpine (MK-801), cause hyperlocomotion and stereotypies [7-9]. The 
hyperactivity is considered to be due predominantly to activation of D2 receptors 
in the nucleus accumbens, whereas stereotypies are caused by stimulation of 
D2 receptors in the caudate-putamen [10]. These behaviors have been 
potentially related to positive symptoms of schizophrenia [11-13]. Acute NMDA 
receptor antagonism has also been reported to increase the release of 
glutamate [14-18], dopamine [19, 20], and serotonin (5-HT) [8, 16-18, 21, 22] in 
the medial prefrontal cortex (mPFC). It has been proposed that stimulation of 
NMDA receptors on the GABA inhibitory interneurons within the cortex leads to 
the release of GABA, which would inhibit glutamatergic neurons and the 
subsequent release of glutamate. Blockade of such NMDA receptors would 
therefore decrease GABAergic inhibitory tone and result in an enhanced activity 
of pyramidal neurons within the cortex [14, 23, 24] leading to downstream 
changes in other transmitters. Indeed, GABAergic interneurons in limbic cortex 
and hippocampus are more sensitive than pyramidal neurons to the action of 
NMDA receptor antagonists [25, 26]. In addition, reduced GABAergic function 
would alter the synchronous firing patterns of cortical neurons, which may 
underlie information-processing deficits present in patients with schizophrenia 
[27]. 
 Various studies have demonstrated that the interactions among 
dopamine, 5-HT and glutamate play an important role in the pathophysiology of 
schizophrenia and that receptors for these transmitters are involved in the 
action of antipsychotic drugs. Increased activity of the mesolimbic dopamine 
system is believed to underlie the positive or psychotic symptoms of 
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schizophrenia and decreased activity within the mesocortical dopamine system 
is believed to reflect negative symptoms and cognitive function also seen in this 
illness [28-32]. All available antipsychotic drugs posses some degree of 
dopamine D2/D3 receptor antagonism, and blockade of dopamine D2/D3 
receptors within the mesolimbic pathway reduces psychotic symptoms [33]. As 
a matter of fact, a good correlation exists between the clinical efficacy of 
antipsychotic drug and their affinity for D2 receptor [34, 35]. Furthermore, most 
antipsychotic drugs display a dose-dependent threshold of D2/D3 receptor 
occupancy for their therapeutic effects [36]. However, the necessity of D2/D3 
receptor blockade for therapeutic action has been challenged recently by the 
finding that drugs that attenuate glutamate release, without acting directly on 
dopamine receptors, are beneficial for positive and negative symptoms [37]. 
 Several atypical antipsychotic drugs, on the other hand, are 
characterized by a lower affinity for D2/D3 and higher affinity for 5-HT2A 
receptors, which has been proposed to confer a superior efficacy and tolerability 
[38, 39]. The lower occupancy of dopamine D2/D3 receptors appears to be 
responsible for causing fewer extrapyramidal side-effects (EPS) [40]. In addition 
to the predominant role of the D2/D3 receptor in the current treatment of 
psychotic symptoms, dopamine D1 receptors have been implicated in 
schizophrenia [41, 42]. This line of evidence has been recently highlighted by 
the finding that cognitive/negative symptoms in schizophrenia are associated 
with a reduction of prefrontal dopamine D1 receptor binding [43]. Some atypical 
antipsychotic drugs may also have affinity for other transmitter receptors such 
as serotonin 5-HT1A, α-adrenergic, histamine H1, and muscarinic receptors, 
which may affect their efficacy and side-effect profile [44, 45]. Thus, there is 
some evidence for the importance of 5-HT1A receptor agonists in certain 
aspects of the pharmacotherapy of schizophrenia [46-49]. Furthermore, 5-HT1A 
receptor agonists have been shown to reduce the incidence of EPS in 
schizophrenia patients treated with haloperidol [50, 51]. With regard to α-
adrenergic mechanisms, many clinically effective antipsychotic drugs (both 
classical and atypical) possess α1-adrenoceptor antagonist properties [44, 52], 
which has been postulated to be clinically relevant [53]. However, although 
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central α1-adrenoceptors may regulate sensorimotor gating altered in 
schizophrenia [54], there are not studies dealing with the occupancy of α1-
adrenoceptors in individuals under antipsychotic treatment. 
 In the animal setting, most studies have shown that atypical, but not 
typical, antipsychotics block the effects of NMDA receptor antagonists on 
prepulse inhibition (PPI) of the startle response [55]. In addition, atypical 
antipsychotic drugs, but not haloperidol, increases extracellular DA 
concentration in the PFC [56, 57] and prevent the brain increase in regional 2-
deoxyglucose uptake induced by ketamine [58]. We have shown recently that 
the local perfusion of antipsychotic drugs decreased extracellular 5-HT in the 
mPFC [59, 60]. Stimulation of 5-HT1A and blockade of 5-HT2A receptors might 
contribute to this effect since both types of compounds were able to prevent the 
increases in 5-HT and glutamate, as well as cognitive deficits induced by NMDA 
receptor antagonists [16, 17, 61, 62]. In contrast, raclopride and eticlopride 
(dopamine D2/D3 antagonists) and SKF 38393 (dopamine D1/D5 agonist) 
prevented the increase of glutamate (but not that of 5-HT) induced by MK-801 
[62]. Furthermore, clozapine and haloperidol attenuated PCP-induced increase 
in cortical glutamate [63], as well as the elevated firing of a population of mPFC 
pyramidal neurons elicited by PCP or MK-801 [64, 65]. Interestingly, clozapine 
exhibited a leveling effect on the firing of pyramidal cells in the mPFC, 
increasing the activity of neurons with low baseline firing rates and decreasing 
the activity of neurons with higher firing rates [64]. This fine-tuning effect might 
contribute to the unique therapeutic efficacy of clozapine in schizophrenia. 
 In a previous study we showed that both clozapine and haloperidol 
blocked the MK-801-induced increase in glutamate in rat mPFC, whereas only 
clozapine was able to block the increased efflux of 5-HT [18]. In addition, we 
also showed that antagonism at dopamine D2 receptors and agonism at 
dopamine D1 receptors resulted in blockade of the effects of MK-801 on mPFC 
glutamate but not 5-HT. In contrast, 5-HT2A and α1-adrenergic receptor 
antagonists, as well as 5-HT1A receptor agonist, were able to prevent the 
increase in 5-HT and glutamate elicited by MK-801 [62]. In the present study we 
set out to replicate such findings using a wider range of concentrations and 
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extend them to other typical (chlorpromazine) and atypical (olanzapine) 
antipsychotic drugs. To this end, intracerebral microdialysis in the mPFC was 
used under the same experimental conditions described previously [18, 63]. 
The choice of prefrontal cortex was accounted for by its pivotal involvement in 
higher brain functions such as executive tasks and cognition [66] known to be 
disrupted in schizophrenia [67] and in animal models [68]. Despite the 
importance of mPFC in the etiology and pharmacotherapy of schizophrenia, it is 
worth noting that the effects of such compounds in other brain regions may also 
be crucial for the treatment of the illness. From a methodological point of view it 
is also important to note that antipsychotic drugs and selective compounds were 
delivered in the mPFC by reverse dialysis. Despite the in vitro affinity (10-8-10-9 
M) of antipsychotics and selective compounds used in the present study for 
serotonergic and adrenergic receptors, the use of concentrations in the 
micromolar range is required in in vivo microdialysis to significantly affect 
neurotransmitter receptors (e.g. [69, 70]). This is due to the fact that effective 
concentration at receptors is limited by the low application rate (in the low 
nmol/h range) and the continuous clearance of the applied drug by the 
cerebrospinal fluid. Moreover, a substantial number of post-synaptic receptors 
in mPFC neurons must be recruited to activate/inhibit the mPFC-raphe circuit 
and elicit changes in mPFC 5-HT release [71, 130]. 
 
IS CORTICAL 5-HT TRANSMISSION RELATED TO “ATYPICALITY”? 
The term “atypical” referred to an antipsychotic drug was first applied to 
clozapine because this drug was devoid of the overt EPS and increased 
prolactin secretion seen in humans treated with neuroleptics. By comparison 
with the pharmacological profile of clozapine, it is considered that atypical 
antipsychotic drugs are relatively more potent serotonin 5-HT2A antagonists 
than dopamine D2 antagonists (see [39] for review). More recently, the multi-
receptor pharmacology of atypical antipsychotics has included other features 
such as serotonin 5-HT1A and dopamine D1 agonism, dopamine D2 partial 
agonism as well as α1-adrenergic antagonism [46, 53, 72, 73]. 
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 The effects of antipsychotic drugs on extracellular 5-HT in the mPFC are 
far from conclusive [18, 61, 74, 75]. In general, both typical and atypical 
antipsychotics seem to decrease or leave unchanged cortical 5-HT although the 
particular effect might depend on the experimental conditions and/or dose of the 
drug. However, there seems to be a concurrence of results showing that 
risperidone increases cortical dialysate 5-HT, an effect which is probably related 
to its antagonistic action at α2-adrenoceptor, and seems to take place at the 
nerve terminal level [74]. In line with this assumption, Hertel and coworkers [76] 
demonstrated that idazoxan, an α2-adrenoceptor antagonist, in combination 
with raclopride (dopamine D2/D3 receptor antagonist), exerted a clozapine-like 
antipsychotic effect on phencyclidine-treated animals. Thus, the role of mPFC 
5-HT in the mechanism of action of atypical antipsychotic drugs appears 
equivocal. Nevertheless, a different issue that has been addressed in the 
present study is the role of cortical 5-HT in the action of antipsychotics in an 
animal model of schizophrenia. 
 Previous studies have demonstrated that NMDA receptor antagonists 
augment the firing rate of putative pyramidal neurons within the mPFC [65, 77, 
78], which results in an increased efflux of glutamate and 5-HT. These effects 
are accounted for by an overstimulation of cortical AMPA-dependent 
glutamatergic transmission because they were abolished by intra-mPFC 
perfusion of an AMPA receptor antagonist [18, 79]. In line with previous 
research [8, 14, 15], MK-801 increases glutamate release onto AMPA/kainate 
receptors leading to an enhanced glutamatergic output from mPFC neurons 
(including those projecting to the dorsal raphe nucleus) thereby increasing 
serotonergic cell firing and cortical 5-HT release. Furthermore, it has been 
shown that blockade of AMPA/kainate receptors in the prefrontal cortex 
inhibited PCP-induced locomotion and stereotypy [80]. The antipsychotic action 
would therefore result from a prevention of the effects resulting from this cortical 
hyperglutamatergia. 
 In an initial study carried out in our lab we showed that pretreatment with 
atypical antipsychotic drugs such as clozapine and olanzapine suppressed the 
increased release of 5-HT in the mPFC elicited by phencyclidine (PCP) and 
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ketamine whereas haloperidol failed to do so [22]. Subsequently we 
demonstrated that clozapine and haloperidol were able to block the increase in 
cortical glutamate produced by MK-801, but only clozapine reduced the 
increase in 5-HT [18]. In addition, the mPFC appeared to be the preferential site 
of action of these drugs inasmuch as their effects were seen after local infusion 
through a dialysis probe. As shown in Fig. (1), this differential action has been 
replicated and confirmed also for chlorpromazine (typical antipsychotic) and 
olanzapine (atypical antipsychotic). The fact that all four antipsychotic drugs 
tested are able to block the effect of MK-801 on extracellular glutamate is in line 
with recent results showing that both clozapine and haloperidol possess the 
ability to markedly inhibit a subset of mPFC neurons [64]. The most prominent 
features of the pharmacological profile shared by these antipsychotics are 
dopamine D2 receptor and α1-adrenoceptor antagonism [44, 45, 52, 81-83]. 
However, since prazosin can also prevent the increase in dialysate 5-HT 
produced by NMDA antagonists ([22]; Fig. (7) of this study), it was suggested 
that glutamatergic transmission in the mPFC is predominantly dependent on 
dopamine D2 receptors, but not on α1-adrenoceptors. Unlike the actions of 
clozapine and olanzapine, the lack of effect of haloperidol and chlorpromazine 
on cortical 5-HT points to a different regulation of the pyramidal cells projecting 
to the dorsal raphe nucleus (DR). Because only 5% of pyramidal neurons in 
layer V of the mPFC project to the dorsal raphe nucleus [84], it is conceivable 
that, under conditions of increased 5-HT and glutamate transmission in the 
mPFC following the administration of NMDA antagonists, blockade of D2 
receptors by antipsychotic drugs might be able to inhibit cortical output 
(blockade of increased glutamate efflux), although sparing mPFC → DR 
projections. An alternative explanation could be that cortico-raphe projecting 
neurons might be inhibited by both typical antipsychotics, but not to the extent 
needed to suppress serotonergic firing distally in the DR and the subsequent 
cortical 5-HT release. On the other hand, we hypothesized that 5-HT 
concentration in the mPFC appears to be under the control of multiple 
monoamine receptors, which is coincident with the multi-receptor profile of 
atypical antipsychotics. 
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EFFECTS OF DOPAMINERGIC COMPOUNDS 
In accord with our hypothesis, we have shown that two different dopamine D2 
receptor antagonists, raclopride and eticlopride, elicited the same effect than 
that of haloperidol and chlorpromazine ([62]; present study). Raclopride binds 
with equal affinity to D2 and D3 receptors and has negligible affinity for D4 
receptors [85], and eticlopride possesses equal selectivity for D2 and D3 
receptors [86], but 10-fold greater affinity than raclopride for both receptors [87]. 
Eticlopride also interacts with D4 receptors [83]. It could be argued that the lack 
of effect of D2/D3 antagonists on cortical 5-HT can be accounted for by the low 
concentration of antagonists used. However, as shown in Fig (2), a higher 
concentration of raclopride (100 µM) produced similar results, i.e. blockade of 
MK-801-induced effects on glutamate but not on 5-HT. Differences in the 
receptor populations present in layer V of the mPFC and the distinct 
pharmacological profile of clozapine, olanzapine, chlorpromazine and 
haloperidol (Table 1), could provide the anatomical substrate for this differential 
effect. Altogether, it appears that serotonergic transmission in the mPFC is 
regulated by the concurrent participation of multiple transmitter receptors, 
whereas glutamatergic transmission is strongly dependent on dopamine D2 
receptor activation. Further evidence of the regulation of glutamate release in 
the mPFC by dopamine D2 receptors is provided by electrophysiological 
studies. Thus, the augmented efflux of dopamine elicited by the blockade of 
NMDA receptors [11, 19, 88] may promote dopamine D2-induced burst firing 
only in a small subset of pyramidal cells of the mPFC [89], possibly in those 
cells enriched in dopamine D2 receptors. However, dopamine D2 receptors are 
located not only in pyramidal cells, but also in GABA interneurons [90-93]. 
Further, tyrosine hydroxylase-positive terminals have been observed in 
apposition with GABA interneurons [94, 95]. Among the different types of 
cortical GABA interneurons, it has been shown that dopamine acts almost 
exclusively on those containing parvalbumin (PV) [92, 96], which target the 
perisomatic compartment of pyramidal cells [97, 98]. In addition, 
immunocytochemistry studies have reported that PV interneurons express both 
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dopamine D1 and D2 receptors [92]. From a physiological viewpoint, dopamine 
exerts a tonic inhibitory action on PV interneurons through D2 receptors [99, 
100]. In addition, evidence from a postmortem study has indicated that, in the 
anterior cingulate cortex of schizophrenics, there is a shift of dopaminergic 
terminals from pyramidal cells to GABA interneurons [101]. This dopamine 
could then act on D2 receptors located in these interneurons thereby reducing 
the release of GABA with the subsequent disinhibition of pyramidal cells. In the 
animal model setting that we used, an excessive release of dopamine following 
MK-801 administration [19] might lead to a further reduction in GABAergic 
inhibition, which would result in an impairment of the intrinsic cortical circuitry. In 
fact, this has been postulated to occur in the brain of schizophrenics [102-104]. 
Dopamine D2 antagonists would dampen the inhibitory action of dopamine 
overflow on GABA interneurons, thus elevating GABA release and reducing 
cortical glutamatergic output induced by MK-801. The relevance of PV 
interneurons in this process is underscored by two facts: 1) in rodents 50% of all 
GABA neurons contain PV [105] and 2) PV neurons are thought to play a 
predominant role in gamma oscillations [106-108]. A subtype of dopamine D2 
receptor that has received attention recently is the D4 receptor. The dopamine 
D4 receptor is of interest because of its localization in limbic structures 
associated with the regulation of mood and cognition, such as cerebral cortex 
and hippocampus [109, 110]. In addition, clozapine and olanzapine have 
significant affinities at the dopamine D4 receptor (Table 1), which supports the 
role of this receptor as a potential target for antipsychotic drugs. For these 
reasons, it was deemed of importance to examine the effects of a dopamine D4 
receptor antagonist (L-745,870) on the MK-801-induced increases in cortical 5-
HT and glutamate. Intracortical pretreatment with L-745,870 prevented the 
effects of MK-801 on glutamate, but not those on 5-HT (Fig (3)). Although there 
is histological evidence of the presence of dopamine D4 receptors in the mPFC 
of rodents, controversy exists as regards to the level of expression [91, 111-
115]. There is consensus, however, that the prefrontal cortex depicts a 
prominent expression of this receptor [91, 110, 114, 115], which is expressed in 
both pyramidal and GABAergic cells [91, 110, 114]. Our results are consistent 
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with a localization of dopamine D4 receptors in GABAergic interneurons 
although it remains to be determined the phenotype of such cells. 
 The regulation of prefrontal function by dopamine involves not only D2, 
but also D1 receptors. In fact, dopamine D1 agonists enhance cortical 
dopaminergic transmission, which is postulated to be good against cognitive 
and negative symptoms [116]. Indeed, the systemic administration of a low 
dose of a dopamine D1 receptor agonist ameliorates cognitive dysfunction 
induced by MK-801 although increases stereotypy and locomotor activity 
(model of psychotic symptoms) at higher doses [117]. Our results show that 
dopamine D1 agonism elicits comparable effects to those of dopamine D2 
antagonists, i.e. a reduction of MK-801-induced increase of cortical glutamate 
[62]. However, when the concentration of the dopamine D1 agonist, SKF-
38393, was increased to 100 µM, the elevation of 5-HT elicited by MK-801 was 
abolished (Fig (4)). However, it remains to be determined the potential clinical 
relevance of this effect. Although dopamine D1 receptors are expressed by 
deep layer cortical pyramidal neurons [93, 118, 119,], they are also localized to 
GABA-containing interneurons [92, 93, 119, 120]. Since the effect of SKF-
38393 is difficult to reconcile with an action on excitatory D1 receptors located 
on pyramidal neurons, a more plausible explanation is that SKF-38393 would 
bind to dopamine D1 receptors of GABAergic neurons, thereby turning on 
GABAergic inhibition, which would block the increase in glutamate efflux 
induced by MK-801. The dopamine D1 receptor family is comprised of two 
subtypes: D1 and D5. Inasmuch as the D1 subtype seems to be predominant in 
cortical PV interneurons [120, 121], it is conceivable that, in the conditions of 
the present study, the blockade of MK-801-induced increase in cortical 
glutamate is accounted for by an action of SKF-38393 on D1 receptors located 
in PV interneurons. However, the blockade of the effects on 5-HT might also 
suggest the presence of D1 receptors in another subpopulation of GABAergic 
interneurons that influence mPFC output to the raphe nuclei (Fig (8)). 
 Altogether our results suggest that D2 antagonists and D1 agonists might 
end up with the same response, i.e. to restore cortical GABA efflux in order to 
prevent an excessive glutamatergic transmission following MK-801 
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administration. Furthermore, our results are also consistent with the proposal 
that D1 receptor activation requires phasic dopamine release whereas D2 
receptors are continuously driven by basal, tonic dopamine release [122]. 
 
EFFECTS OF SEROTONERGIC COMPOUNDS 
In contrast to dopamine D2 receptor antagonists, the selective 5-HT2A 
antagonist, M100907 [123], prevented the increase in 5-HT and glutamate 
elicited by MK-801 in a concentration-dependent manner (Fig (5)). This agrees 
with prior work using a competitive NMDA receptor antagonist [16] and could 
reflect a reduction of a heightened prefrontal output (including that projecting to 
the DR) following MK-801. In fact, at the concentration of 300  µM, M100907 
decreased MK-801-induced 5-HT level below baseline values. Previous work 
from our lab has also shown that 5-HT2A antagonism is able to prevent other 
paradigms of higher serotonergic transmission in the mPFC, such as intra-
mPFC perfusion of S-α-amino-3-hydroxy-5-methyl-4-isoxazole-4-propionic acid 
(S-AMPA), 2,5-dimethoxy-4-iodoamphetamine (DOI) and the α1-adrenoceptor 
antagonist cirazoline [59, 124], as well as thalamic disinhibition [60]. 5-HT2A 
receptors are largely localized to apical dendrites of pyramidal neurons [125, 
126], a cellular zone that receives inputs from different cortical areas, allowing 
integration within cortical layers and between different cortical areas. For this 
reason, 5-HT2A antagonists are in a unique position to compensate for the 
increased cortico-cortical transmission that probably occurs after MK-801 
administration and the pharmacological conditions mentioned above. Although 
there is evidence that 5-HT2A receptors are also present in cortical GABAergic 
interneurons of the rat mPFC [125, 127], our results points to a predominant 
effect of M100907 on the population of receptors located in pyramidal neurons 
following MK-801 administration. 
 Besides 5-HT2A receptor antagonism, 5-HT1A receptor agonism is also 
able to block the increase in 5-HT and glutamate elicited by MK-801 with a 
comparable potency (Fig (6)). Another study has shown that the 5-HT1A 
receptor agonist 8-OH-DPAT also prevents the increase in cortical 5-HT and 
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glutamate evoked by a competitive NMDA antagonist [17]. As for the effects of 
M100907, the reduction of 5-HT is probably caused by a decrease in the activity 
of pyramidal cells projecting to the DR [128, 129], which would ease this 
nucleus from a tonic excitatory input, thereby decreasing the activity of 5-HT 
cells [130]. The 5-HT1A receptor agonist repinotan (BAY x 3702) [131] has 
proved also effective in blocking the increased 5-HT release induced by intra-
mPFC perfusion of S-AMPA, DOI and cirazoline [59, 124], as well as thalamic 
disinhibition [60]. The additional blockade of increased glutamatergic 
transmission suggests that 5-HT1A receptor activation in the mPFC potently 
attenuates the action of agents that enhance the activity of pyramidal neurons, 
an effect shared by several different treatments and involving the stimulation of 
AMPA/kainate receptors in the mPFC [18, 79]. Furthermore, the crucial 
localization of 5-HT1A receptors in the perisomatic domain of cortical pyramidal 
neurons of the rat prefrontal cortex [132] might explain the powerful effects of 5-
HT1A receptor agonists. Both 5-HT2A and 5-HT1A receptors show a ~80% co-
localization in the mPFC [124] with a high level of expression in pyramidal cells 
labeled by vGluT1 [127]. Altogether, this provides the anatomical support for an 
action of serotonergic compounds on pyramidal cells of the mPFC. Although 5-
HT2A and 5-HT1A receptors are also expressed in cortical GABAergic 
interneurons of the rat [125, 127, 133], they do not seem to play a role in the 
control of cortical 5-HT and glutamate in the conditions of the present work. 
 
EFFECTS OF α1-ADRENOCEPTOR ANTAGONISTS 
As for 5-HT2A antagonists and 5-HT1A agonists, the intra-mPFC administration 
of the α1-adrenoceptor antagonist prazosin [134] also blocked the MK-801-
induced increase in 5-HT and glutamate (Fig (7)). Although α1-adrenoceptors 
are largely co-expressed with 5-HT2A receptors (>80%) and are localized to 
both pyramidal and GABAergic cells (N. Santana, G. Mengod and F. Artigas, 
unpublished results) in the mPFC, the effects of prazosin seen in previous [62] 
and the present study are more congruous with a blockade of α1-adrenoceptors 
located on pyramidal neurons, including those in layer V that project to the 
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dorsal raphe nucleus. The mechanism of action of prazosin is most likely similar 
to that of M100907 inasmuch as both 5-HT2A and α1-adrenoceptors are coupled 
to the same intracellular signaling mechanisms (phospholipase C) and mediate 
the excitatory actions of 5-HT and noradrenaline on pyramidal neurons of the 
mPFC [128, 135]. Moreover, the fact that 5-HT2A and α1-adrenoceptors are 
localized to the same cortical areas [136-138] provides a neuroanatomical 
support for the parallel action of 5-HT2A and α1-adrenoceptor antagonists. The 
main difference in the cortical laminar distribution between 5-HT2A and α1-
adrenergic receptors is that the latter are separated in two bands around layer V 
[139, 140]. In line with the present work, previous studies carried out in our 
laboratory have revealed that the perfusion of prazosin in the mPFC prevented 
the increase of 5-HT elicited by the cortical application of cirazoline, DOI and S-
AMPA [60], as well as thalamic disinhibition [60]. Because all these compounds 
do not interact directly with each other’s receptors their effects need to be 
interpreted not at receptorial level, but at cellular (pyramidal) level. This is 
correspondence with the role of pyramidal cells of the mPFC in integrating 
multiple inputs from cortical as well as subcortical areas [141-143]. 
 
IMPLICATIONS FOR ANTIPSYCHOTIC ACTION 
The findings of the present and previous [18, 62] work from our laboratory 
suggest that excessive glutamate transmission in the mPFC (resulting from 
NMDA receptor blockade) may be associated with some positive symptoms of 
schizophrenia, inasmuch as they are better treated by drugs that possess some 
degree of dopamine D2 receptor antagonism (a characteristic of the great 
majority of marketed antipsychotic drugs). In contrast, impairment of 
serotonergic pathways in the mPFC might rather be related to negative 
symptoms and/or cognitive deficits, conditions for which atypical antipsychotic 
drugs (e.g. clozapine and olanzapine) seem to display superior therapeutic 
efficacy. However, several recent studies have somehow challenged this 
purported higher efficacy in the clinic. Thus, the Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE) study has shown that the typical drug 
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perphenazine is as effective as other atypical drugs in terms of PANSS scores. 
However, olanzapine was the medication that patients stayed on the longest in 
the trial [144]. In similar terms, the Cost Utility of the Latest Antipsychotics in 
Severe Schizophrenia (CUtLASS) study also concluded that second-generation 
(atypical) antipsychotics do not offer significant clinical benefits over first-
generation (typical) drugs when prescribed to patients with schizophrenia [145]. 
Altogether these studies illustrate the difficulty of translating from 
experimentally-observable pharmacological differences in the preclinical setting 
to therapeutic advantages. 
Thus, there is a clear need for targeting different transmitter receptors in order 
to achieve better treatment (as well as a lower side-effect profile) of 
schizophrenia. Pharmacological models of schizophrenia based on NMDA 
antagonism, dopaminergic stimulants or serotonergic agonists point to an 
exacerbated glutamatergic transmission, at least in the mPFC. Our results 
suggest that, antagonism at 5-HT2A and α1-adrenergic receptors, as well as 
agonism at 5-HT1A receptors, are able to prevent the excessive glutamatergic 
transmission in the mPFC produced by such different conditions. In line with 
these results, it has been shown that 5-HT and selective receptor agonists 
modulate the excitability of cortical neurons and their discharge rate through the 
activation of several receptor subtypes: namely 5-HT1A, 5-HT1B, 5-HT2A/2C and 
5-HT3 [128, 146-152]. Atypical antipsychotic drugs that exhibit 5-HT2A 
antagonism and/or 5-HT1A agonism, such as clozapine, increase dopamine 
efflux in the mPFC of rodents [57, 153-157], which is potentially involved in the 
improvement of negative symptoms and cognitive dysfunction in schizophrenia 
[154, 155, 158, 159]. This effect appears to be dependent on the presence of 
intact 5-HT1A receptors [57, 157]. Given that some of these drugs (e.g. 
olanzapine) do not depict affinity for 5-HT1A receptors (Table 1), it would seem 
that the 5-HT1A receptor has a permissive role in this action, rather than being 
directly responsible. However, the increase in dopamine efflux produced by 
atypical antipsychotic drugs, including olanzapine, is inhibited by the 5-HT1A 
receptor antagonist WAY 100635 [155] and absent in 5-HT1A receptor knockout 
mice [57], which suggests a pivotal role for 5-HT1A agonism in some of the key 
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properties desired for novel antipsychotic drugs. This concept is supported by 
clinical trials with partial 5-HT1A receptor agonists, which report the ability of 
these compounds not only to reduce the incidence of EPS [46] but also to 
enhance some domains of cognitive function [47]. However, inconsistent results 
have been found depending on the antipsychotic drug and the 5-HT1A receptor 
agonist used (reviewed in [160]). 
 With regard to α1-adrenoceptors, preclinical studies have revealed that 
the blockade of α1-adrenoceptors by prazosin potentiated the antipsychotic-like 
effect of dopamine D2 receptor antagonists [161]. In addition, all antipsychotic 
drugs used in this study display high in vitro affinity for α1-adrenoceptors (Table 
1), which suggests a potential antipsychotic role of α1-adrenoceptor antagonism 
in the pharmacotherapy of schizophrenia. However, the use of drugs that 
possess a high α1-adrenoceptor antagonism in vivo is limited because their 
cardiovascular side-effects (hypotension, arrhythmia). 
 In summary, the intra-mPFC administration of M100907, repinotan and 
prazosin prevents MK-801-induced increase in 5-HT and glutamate, effects that 
are comparable to those obtained with clozapine and olanzapine [62; present 
study], and can be associated to a direct reduction the excitability of a 
subpopulation of pyramidal neurons in the mPFC (Fig (8)). Thus, it is possible 
that 5-HT2A and α1-adrenergic receptor antagonism, as well as 5-HT1A receptor 
agonism, may relate to a better treatment of most symptoms of schizophrenia. 
In fact, preclinical studies have shown that 5-HT2A antagonists and 5-HT1A 
agonists can alleviate cognitive deficits induced by NMDA receptor antagonists 
[61]. Because each of these receptor components do not confer antipsychotic 
properties individually, it is conceivable that a combined effect is necessary to 
achieve this goal. 
 In a recent work, Homayoun and Moghaddam demonstrated that 
clozapine has the unique feature of increasing the activity of putative pyramidal 
neurons with low baseline firing rates and decreasing the activity of neurons 
with higher firing rates in prefrontal cortex [64]. Given that antagonists at D2/D3, 
D4, 5-HT2A receptors and a dopamine D1 receptor antagonist are all able to 
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increase basal extracellular glutamate on their own (Table 2), but they prevent 
the increase of glutamate release evoked by MK-801, the dual effect of 
clozapine can result from its interaction with such monoamine receptors, and 
this might be related to the pro-cognitive effects of the drug. It would be 
interesting to examine whether this effect of clozapine is shared by other 
atypical antipsychotic drugs with a similar pharmacological profile. 
 Unlike serotonergic and adrenergic compounds, the effects of 
dopaminergic compounds have been attributed to an increase in cortical 
inhibition responsible for a reduction of an excessive glutamatergic stimulation 
following NMDA antagonism ([62]; present study). This implies the localization 
of dopamine D1/D5, D2/D3 and D4 receptors in a subpopulation of GABA 
interneurons (possibly those containing PV). Interestingly, the finding that a high 
concentration of the SKF 38393 is also able to prevent the MK-801-induced 
increase of cortical 5-HT seems to suggest that D1/D5 receptors are also located 
in a different set of GABA interneurons, perhaps those containing 
cholecystokinin [162, 163]. Clozapine has been shown to enhance dopamine 
D1 receptor-mediated neurotransmission [72, 164]. Therefore, the pro-cognitive 
action of clozapine could also result from its action on dopamine D1 receptors. 
Alternatively, it has also been suggested that the action of clozapine could 
involve potentiation of NMDA transmission (see [165] for review). Our results 
support a similar view for olanzapine. On the other hand, blockade of dopamine 
D2/D3 receptors may be in the front line of the pharmacological treatment of 
schizophrenia because dopamine D2/D3 antagonists would increase GABA 
inhibition directly, thus restoring cortical synchrony. 
The conclusions raised in previous [62] and the present study are 
established as a result of the analogies present in the action of antipsychotic 
drugs and selective agonists and antagonists for monoaminergic receptors. 
However, it remains to be determined if different effects may emerge from a 
combination of multiple interactions among these receptors. Furthermore, as a 
general rule for psychiatric illnesses, caution must be taken in extrapolating the 
results obtained in an animal model to a clinical setting. 
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FUTURE TRENDS 
From the beginning of pharmacotherapy of schizophrenia, medicine cases have 
been filled with drugs that shared the characteristic of being dopamine D2 
receptor antagonists. First generation typical antipsychotics like haloperidol and 
chlorpromazine potently block dopamine D2/D3/D4 and α1-adrenergic receptors. 
The blockade of dopamine D2 receptors in the PFC and the nucleus 
accumbens appears to be beneficial for psychotic symptoms (delusions, 
hallucinations). However, the same action in other areas of the brain can cause 
severe EPS and hyperprolactinemia [33]. Second generation atypical 
antipsychotic drugs like clozapine and olanzapine keep some degree of 
dopamine D2/D3/D4 antagonism, but they display a higher antagonism at 5-
HT2A/2C receptors. These features seem to be more effective for negative 
symptoms and cognitive deficits although some side-effects (weight gain, 
impairment of glucose and lipid metabolism) may appear [166]. However, this 
group of drugs is not homogeneous, and a recent meta-analysis of randomized 
controlled trials has shown that only four of these second-generation drugs 
(amisulpride, clozapine, olanzapine and risperidone) were better than first-
generation antipsychotic drugs for overall efficacy [167]. The other second-
generation drugs (quetiapine, sertindole, ziprasidone, zotepine) were not more 
efficacious than the first-generation drugs, even for negative symptoms. 
Therefore, efficacy on negative symptoms does not seem to be a core 
component of atypicality. Third generation antipsychotic drugs like aripiprazole 
and bifeprunox improve both positive and negative symptoms of schizophrenia 
without producing EPS or increases in serum prolactin [168, 169]. The unifying 
features of this third generation antipsychotics are the association of D2/D3 
interaction (antagonism or partial agonism) with 5-HT1A receptor activation 
without the requirement for 5-HT2A receptor blockade. More recently it has been 
shown that drugs that interact with mGluR also have potential for the treatment 
of schizophrenia [37, 170, 171]. However, a significant proportion of patients still 
do not experience complete remission of their positive symptoms and 
negative/cognitive symptoms remain poorly treated. In recent years, research 
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and development efforts have sought novel "atypical" antipsychotic drugs that 
would offer the therapeutic advantages of clozapine without the associated risk 
of side effects. 
 In the search for reliable biomarkers to be used in R+D of newer drugs, 
our results first suggest that the blockade of an exacerbated 5-HT release in the 
mPFC induced by NMDA antagonists can be a useful biochemical marker of 
“atypicality” of antipsychotic drugs. Although this has been established for 
clozapine and olanzapine (drugs that display a similar pharmacological profile), 
further research is needed to determine whether this is a distinct feature of 
other second generation antipsychotic drugs and, most interestingly, if this 
holds also true for third generation antipsychotics (which represents receptor 
mechanisms that include dopamine D2/D3 receptor partial agonism). 
 GABAergic interneurons in prefrontal cortex play a critical role in cortical 
circuits by providing feedforward and feedback inhibition and synchronizing 
neuronal activity [172, 173]. In this regard, we also propose that blockade of 
dopamine D2/D3/D4 as well as dopamine D1 agonism in the mPFC may lead to a 
restoration of cortical GABA inhibition and synchrony alleged to be impaired in 
schizophrenia [102-104, 174]. Further support for this hypothesis has been 
obtained recently in our lab showing that both clozapine and haloperidol have 
the ability of reverse the effects of PCP on pyramidal cell firing and cortical 
synchronization [65]. However, it is also possible that the same effect is caused 
by different mechanisms, i.e. blockade of dopamine D2/D3/D4 receptors 
(haloperidol) or 5-HT2A receptors (clozapine). Further research is needed to 
verify such different alternatives. 
 On the other hand, antagonism at 5-HT2A and α1-adrenergic receptors, 
as well as agonism at 5-HT1A receptors may also be helpful by suppressing an 
excessive stimulation of pyramidal cells. One of the most important issues in 
this field is the fact that all these monoamine receptors implicated in the 
pharmacological treatment of schizophrenia are present in both pyramidal cells 
and GABA interneurons in the mPFC [93, 127]. Therefore, the question arises 
as to what factors determine the binding of a drug predominantly to one of these 
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cellular populations. With this in mind, newer antipsychotics would target 
receptors responsible for stimulating cortical GABA inhibition and diminishing 
excessive excitability of pyramidal cells without the undesired effects of similar 
actions in other areas of the brain. In addition, the regulatory changes of the 
complex formed by 5-HT2A and mGluR2 receptors presumed to be involved in 
the altered cortical processes [175] also suggests that this receptor complex is 
a promising new target for the treatment of psychosis. 
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Table 1. In vitro binding affinities of the four antipsychotics used in the present 
study, expressed in Ki values (nM). 
Receptor Clozapine Olanzapine Haloperidol Chlorpromazine
D1 85 31 210 56 
D2 125 11 1 2 
D3 473 27 2 9 
D4 35 21 5 12 
5-HT1A 770 >10,000 2,600 116* 
5-HT2A 12 2 78 2 
5-HT2C 8 11 1,500 25 
α1-adrenergic 7 7 6 1 
H1 histamine 6 7 >730 9 
Muscarinic 2 2 >1,500 60 
 
Data taken from references [44, 45, 52, 81-83]. 
*Data from human cloned 5-HT1A receptors. 
 
 
 
 
 
 
 
 
  
Table 2. Changes in extracellular 5-HT and glutamate in the mPFC as a result 
of the action of intra-mPFC administration of drugs on different monoamine 
receptors. (=) unchanged, (↑) increase and (↓) decrease. 
 
Receptor action  Changes in 5-HT  Changes in glutamate 
 
D2/D3 antagonism   =    ↑ 
D4 antagonism   =    ↑ 
D1 agonism     ↓    ↑ 
5-HT1A agonism   ↓    = 
5-HT2A antagonism   ↓    ↑ 
α1-adrenoceptor antagonism ↓    = 
 
Data taken from reference [60, 62] and X. López-Gil, F. Artigas and A. Adell 
(unpublished results). 
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FIGURE LEGENDS 
 
Figure 1. Effects of the intra-mPFC perfusion (line) of 300 µM of clozapine 
(CLZ), olanzapine (OLZ), chlorpromazine (CPZ) and haloperidol (HAL) on the 
efflux of 5-HT (A) and glutamate (B) in the mPFC elicited by MK-801 (1 mg/kg, 
i.p.; arrow). Data (mean ± SEM) are expressed as percentage changes of the 
four basal predrug values. Number of animals is given in parentheses. The 
control group received an injection of saline and, for the sake of clarity, is 
depicted as a dotted line. Analysis of variance (ANOVA) shows that all four 
antipsychotic drugs block the increase in glutamate produced by MK-801, but 
only clozapine and olanzapine are able to block the effect of MK-801 on 5-HT. 
 
Figure 2. Effects of the perfusion of the dopamine D2/D3 antagonist raclopride 
(RAC, 10, 30 and 100 µM) on the efflux of 5-HT (A) and glutamate (B) in the 
mPFC elicited by MK-801 (1 mg/kg, i.p.; arrow). Data are based on integrated 
area under the curve (AUC) analysis of 4-h perfusion, and expressed as the 
percentage change from the control group depicted as open bar. *p < 0.01 vs. 
control group and §p < 0.01 vs. MK-801 alone (Newman-Keuls test following 
ANOVA). 
 
Figure 3. Effects of the perfusion of the selective dopamine D4 antagonist L-
745,870 (L, 10 and 30 µM) on the efflux of 5-HT (A) and glutamate (B) in the 
mPFC elicited by MK-801 (1 mg/kg, i.p.; arrow). Data are based on integrated 
area under the curve (AUC) analysis of 4-h perfusion, and expressed as the 
percentage change from the control group depicted as open bar. *p < 0.01 vs. 
control group and §p < 0.01 vs. MK-801 alone (Newman-Keuls test following 
ANOVA). 
 
Figure 4. Effects of the perfusion of the dopamine D1/D5 agonist SKF 38393 
(SKF, 1, 10 and 100 µM) on the efflux of 5-HT (A) and glutamate (B) in the 
mPFC elicited by MK-801 (1 mg/kg, i.p.; arrow). Data are based on integrated 
area under the curve (AUC) analysis of 4-h perfusion, and expressed as the 
percentage change from the control group depicted as open bar. *p < 0.01 vs. 
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control group and §p < 0.01 vs. MK-801 alone (Newman-Keuls test following 
ANOVA). 
 
Figure 5. Effects of the perfusion of the selective 5-HT2A antagonist M100907 
(M, 1, 10 and 300 µM) on the efflux of 5-HT (A) and glutamate (B) in the mPFC 
elicited by MK-801 (1 mg/kg, i.p.; arrow). Data are based on integrated area 
under the curve (AUC) analysis of 4-h perfusion, and expressed as the 
percentage change from the control group depicted as open bar. *p < 0.01 vs. 
control group and §p < 0.01 vs. MK-801 alone (Newman-Keuls test following 
ANOVA). 
 
Figure 6. Effects of the perfusion of the selective 5-HT1A agonist repinotan 
(BAY x 3702; BAY, 1 and 30 µM) on the efflux of 5-HT (A) and glutamate (B) in 
the mPFC elicited by MK-801 (1 mg/kg, i.p.; arrow). Data are based on 
integrated area under the curve (AUC) analysis of 4-h perfusion, and expressed 
as the percentage change from the control group depicted as open bar. *p < 
0.01 vs. control group and §p < 0.01 vs. MK-801 alone (Newman-Keuls test 
following ANOVA). Data taken and redrawn from reference [62], with 
permission. 
 
Figure 7. Effects of the perfusion of the selective α1-adrenoceptor antagonist 
prazosin (PRZ, 1, 10 and 100 µM) on the efflux of 5-HT (A) and glutamate (B) in 
the mPFC elicited by MK-801 (1 mg/kg, i.p.; arrow). Data are based on 
integrated area under the curve (AUC) analysis of 4-h perfusion, and expressed 
as the percentage change from the control group depicted as open bar. *p < 
0.01 vs. control group and §p < 0.01 vs. MK-801 alone (Newman-Keuls test 
following ANOVA). 
 
Figure 8. The diagram illustrates the functional relationships between the 
mPFC and its dopaminergic and serotonergic projections from the VTA and the 
DR, respectively. Although all monoaminergic receptors depicted in this figure 
are present in both pyramidal cells and GABAergic interneurons, it is only 
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represented the localization that conforms to the results obtained in the present 
study. 








